Rachelle Bitton, MD
Endocrinology, Diabetes & Metabolism · Lake Success, NYNPI 1770538548
Payments from drug & device makers
Across 176 payments — averaging $30.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Novo Nordisk$606
- Siemens Medical Solutions USA, Inc.$471
- AstraZeneca$357
- Boehringer Ingelheim$282
- Medtronic$272
- plus $2K from 20 others
What the payments were for
- Consulting fees$1,37225%
- Speaking & faculty fees$791%
- Travel & lodging$4809%
- Food & beverage$3,45264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $1,372 |
| Novo Nordisk | 44 | $606 |
| Siemens Medical Solutions USA, Inc. | 2 | $471 |
| AstraZeneca | 20 | $357 |
| Boehringer Ingelheim | 13 | $282 |
| Medtronic(2 entities) | 15 | $272 |
| Abbott | 5 | $233 |
| Insightec,inc | 2 | $233 |
| Lilly USA, LLC | 8 | $173 |
| Amneal Pharmaceuticals LLC | 8 | $172 |
| Merck | 6 | $163 |
| Amgen | 7 | $152 |
| Dexcom, Inc. | 8 | $139 |
| Xeris Pharmaceuticals, Inc. | 7 | $138 |
| Pfizer | 2 | $93 |
| BD | 4 | $76 |
| IBSA Pharma Inc. | 4 | $68 |
| Johnson & Johnson | 2 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Embecta Corp. | 2 | $48 |
| AbbVie | 2 | $47 |
| Tandem Diabetes Care, Inc. | 3 | $46 |
| Insulet Corporation | 3 | $44 |
| Lifescan, Inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PIQRAY$1,372
- MAGNETOM Vida$460
- Exablate$149
- FreeStyle Libre$141
How this compares
$5,383 in reported general payments places this provider in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 85 | $135,822 |
| OzempicSemaglutide | 85 | $131,787 |
| RybelsusSemaglutide | 25 | $56,285 |
| TradjentaLinagliptin | 65 | $51,657 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $48,733 |
| JanuviaSitagliptin Phosphate | 41 | $48,223 |
| FarxigaDapagliflozin Propanediol | 33 | $42,383 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $41,116 |
| ProliaDenosumab | 18 | $31,379 |
| SynjardyEmpagliflozin/Metformin Hcl | 25 | $26,218 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 23 | $23,614 |
| SynthroidLevothyroxine Sodium | 280 | $19,077 |
| Levothyroxine Sodium | 721 | $8,845 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $8,243 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $8,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr | $282 | $221,939187 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $606 | $194,021127 claims |
| MerckJanumet, Januvia, Janumet Xr | $163 | $138,073115 claims |
| AstraZenecaFarxiga | $357 | $42,38333 claims |
| AmgenProlia | $152 | $31,37918 claims |
| AbbVieSynthroid | $47 | $19,077280 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $172 | $8,845721 claims |
| Lilly USA, LLCHumalog | $173 | $2,48412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Lake Success
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.